GlassScriptPhysician profile
Matthew D Glynn
NPI 1417971102
$1,614.60
in general payments reported to CMS, 2019-2025
27 companies · $259 in 2025
The $259 reported for 2025 was less than what a typical Otolaryngology provider received nationally (typical 2025 total: $317).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $243 · 2020: $40.49 · 2021: $181 · 2022: $141 · 2023: $430 · 2024: $320 · 2025: $259.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $957 · Education: $52.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $956.84 |
| Education | $52.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viiv Healthcare Company | $233.16 | 2019-2021 | |
| Aerin Medical INC. | $230.38 | 2023-2025 | |
| Regeneron Healthcare Solutions, INC. | $163.40 | 2019-2025 | Dupixent |
| Glaxosmithkline, LLC. | $163.25 | 2021-2025 | Nucala |
| Genzyme Corporation | $144.88 | 2022-2025 | |
| Intersect Ent, INC. | $89.35 | 2021-2022 | |
| Sanofi-Aventis U.S. LLC | $66.70 | 2021-2023 | |
| Astrazeneca Pharmaceuticals LP | $49.09 | 2023-2024 | Fasenra |
| Convatec INC. | $48.39 | 2024 | |
| Smith+Nephew, INC. | $42.30 | 2025 | Halo, Tula, Rf20000 |
| Novartis Pharmaceuticals Corporation | $37.80 | 2023-2025 | |
| Merck Sharp & Dohme LLC | $37.77 | 2023-2025 | Keytruda |
| Stryker Corporation | $35.43 | 2019 | |
| Integra Lifesciences Corporation | $34.41 | 2024-2025 | Inspira Air, Acclarent Aera, Relieva Spinplus Nav |
| Amgen INC. | $32.26 | 2023-2025 | Tezspire |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Acclarent, INC | $25.86 | 2021-2022 | |
| Ars Pharmaceuticals Operations, INC. | $21.00 | 2025 | Neffy |
| Cochlear Americas | $19.44 | 2025 | Cochlear Nucleus Ci632 Cochlear Implant With Slim Modiolar Electrode, Baha, Osia Osi300 Implant |
| Genentech USA, INC. | $17.65 | 2023 | Xolair |
| Aesculap, INC. | $16.89 | 2023 | Elan 4 |
| Hologic Sales and Service, LLC | $16.83 | 2023 | Coolseal Generator |
| Kaleo, INC. | $16.09 | 2023 | Auvi-Q |
| Medtronic, INC. | $15.64 | 2025 | Propel |
| Ambu INC. | $15.29 | 2024 | |
| Phathom Pharmaceuticals, INC. | $15.02 | 2024 | Voquezna |
| Lilly USA, LLC | $13.81 | 2019 | |
| Medtronic USA, INC. | $12.51 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Glynn listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.